Pediatric-style chemotherapy versus MA alloHCT for Ph-negative ALL in AYAs in first complete remission
Dr. Matthew Wieduwilt
Analysis of patients in the CALGB 10403 study compared pediatric-style chemotherapy versus myeloablative allogeneic hematopoietic cell transplantation for Ph-negative ALL in patients aged 16 to 39 years in first complete remission. Chemotherapy was superior to MA alloHCT for overall survival, disease-free survival, and non-relapse mortality. The incidence of relapse at five years was higher with chemotherapy than with MA alloHCT.
